SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

A minor change in the total revenue was seen in the March 2025 quarter. The total revenue for the quarter stood at Rs. 5277.80 millions against Rs. 5039.20 millions during year ago period.A humble growth in net profit of 12.17% reported in the quarter ended March 2025 to Rs. 316.20  millions from Rs. 281.90 millions.The company reported a good operating profit of 674.60 millions compared to 576.00 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 5277.80 5039.20 4.73 20792.10 21327.90 -2.51 20792.10 21327.90 -2.51
Other Income 45.20 75.20 -39.89 224.00 300.70 -25.51 224.00 300.70 -25.51
PBIDT 674.60 576.00 17.12 2245.70 2615.90 -14.15 2245.70 2615.90 -14.15
Interest 40.30 34.10 18.18 147.60 161.00 -8.32 147.60 161.00 -8.32
PBDT 634.30 541.90 17.05 2098.10 2454.90 -14.53 2098.10 2454.90 -14.53
Depreciation 185.30 164.20 12.85 719.20 628.50 14.43 719.20 628.50 14.43
PBT 449.00 377.70 18.88 1378.90 1826.40 -24.50 1378.90 1826.40 -24.50
TAX 132.80 95.80 38.62 368.90 472.20 -21.88 368.90 472.20 -21.88
Deferred Tax 62.20 45.60 36.40 121.50 102.10 19.00 121.50 102.10 19.00
PAT 316.20 281.90 12.17 1010.00 1354.20 -25.42 1010.00 1354.20 -25.42
Equity 587.10 587.10 0.00 587.10 587.10 0.00 587.10 587.10 0.00
PBIDTM(%) 12.78 11.43 11.82 10.80 12.27 -11.94 10.80 12.27 -11.94

IOL Chem & Pharma Share Price

91.16 5.66 (6.62%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×